 Home > Medical News > Latest Medical News > Arnold Pharma announces the completion of the first patient dosing for Buparlisib's global phase III clinical trial

Arnold Pharma announces the completion of the first patient dosing for Buparlisib's global phase III clinical trial

 Last Update: 2021-04-23
 Source: Internet
 Author: User

Tags

shanghai china

henkel north america

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 15th, Arnold Pharma announced that its oral PI3K inhibitor Buparlisib (AN2025) combined with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in the global multi-center phase III clinical trial has been successful in Shanghai Oriental Hospital, China Complete the first patient's administration.

The study is a randomized, open, multi-center phase III clinical study conducted globally to evaluate the efficacy and safety of Buparlisib combined with paclitaxel or paclitaxel alone in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

The global incidence of head and neck squamous cell carcinoma ranks eighth among malignant tumors, and the mortality rate ranks twelfth, with approximately 840,000 new cases occurring each year.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Arnold Pharma announces that Buparlisib has completed the first patient dosing in the global phase III clinical trial of recurrent or metastatic head and neck cancer

07-09

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Arnold Pharma announces the completion of the first patient dosing for Buparlisib's global phase III clinical trial

Related Articles

Arnold Pharma announces that Buparlisib has completed the first patient dosing in the global phase III clinical trial of recurrent or metastatic head and neck cancer